[
    {
        "id": 5029,
        "drug_name": "TRULICITY (dulaglutide) - REWIND CV outcomes",
        "clinical_trial_id": "NCT01394952",
        "has_trial_insight_page": 0,
        "indication": "Type 2 diabetes",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-02-21",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/trulicityr-dulaglutide-first-and-only-type-2-diabetes-medicine",
        "note": "FDA Approval announced February 21, 2020.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3514,
        "drug_name": "NEXLETOL (bempedoic acid)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hypercholesterolemia ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-02-21",
        "link": "https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=211616",
        "note": "FDA Approval announced February 21, 2020.",
        "company_entity_id": 133,
        "company_ticker": "ESPR",
        "company_name": "Esperion Therapeutics Inc.",
        "company_price": "2.0500",
        "company_change": -0.06999999999999995,
        "company_percent_change": -3.3,
        "company_optionable": 1,
        "company_number_of_shares": 185052705,
        "price_change_sparkline": [
            [
                2.14,
                1706677200
            ],
            [
                2.07,
                1706763600
            ],
            [
                2.19,
                1706850000
            ],
            [
                2.38,
                1707109200
            ],
            [
                2.58,
                1707195600
            ],
            [
                2.63,
                1707282000
            ],
            [
                2.58,
                1707368400
            ],
            [
                2.58,
                1707454800
            ],
            [
                2.6,
                1707714000
            ],
            [
                2.54,
                1707800400
            ],
            [
                2.61,
                1707886800
            ],
            [
                2.66,
                1707973200
            ],
            [
                2.69,
                1708059600
            ],
            [
                2.68,
                1708405200
            ],
            [
                2.61,
                1708491600
            ],
            [
                2.63,
                1708578000
            ],
            [
                2.61,
                1708664400
            ],
            [
                2.63,
                1708923600
            ],
            [
                2.9,
                1709010000
            ],
            [
                2.57,
                1709096400
            ],
            [
                2.51,
                1709182800
            ],
            [
                2.55,
                1709269200
            ],
            [
                2.44,
                1709528400
            ],
            [
                2.4,
                1709614800
            ],
            [
                2.46,
                1709701200
            ],
            [
                2.28,
                1709787600
            ],
            [
                2.19,
                1709874000
            ],
            [
                2.12,
                1710129600
            ],
            [
                2.05,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10929,
        "drug_name": "Barhemsys (amisulpride)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Postoperative nausea and vomiting (PONV)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-02-26",
        "link": "https:\/\/www.drugs.com\/history\/barhemsys.html",
        "note": "Approved February 26, 2020.",
        "company_entity_id": 128,
        "company_ticker": "EGRX",
        "company_name": "Eagle Pharmaceuticals Inc.",
        "company_price": "5.7300",
        "company_change": -0.14,
        "company_percent_change": -2.39,
        "company_optionable": 1,
        "company_number_of_shares": 12986971,
        "price_change_sparkline": [
            [
                5.86,
                1706677200
            ],
            [
                6.08,
                1706763600
            ],
            [
                5.85,
                1706850000
            ],
            [
                5.6,
                1707109200
            ],
            [
                4.9,
                1707195600
            ],
            [
                5.165,
                1707282000
            ],
            [
                5.32,
                1707368400
            ],
            [
                5.32,
                1707454800
            ],
            [
                5.6,
                1707714000
            ],
            [
                5.21,
                1707800400
            ],
            [
                5.25,
                1707886800
            ],
            [
                5.85,
                1707973200
            ],
            [
                5.97,
                1708059600
            ],
            [
                5.99,
                1708405200
            ],
            [
                6.23,
                1708491600
            ],
            [
                5.87,
                1708578000
            ],
            [
                6.25,
                1708664400
            ],
            [
                6.48,
                1708923600
            ],
            [
                6.44,
                1709010000
            ],
            [
                6.27,
                1709096400
            ],
            [
                5.86,
                1709182800
            ],
            [
                6.48,
                1709269200
            ],
            [
                6.29,
                1709528400
            ],
            [
                6.51,
                1709614800
            ],
            [
                6.35,
                1709701200
            ],
            [
                6.25,
                1709787600
            ],
            [
                6.25,
                1709874000
            ],
            [
                5.87,
                1710129600
            ],
            [
                5.73,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2657,
        "drug_name": "NEXLETOL (bempedoic acid) \/ Ezetimibe",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hypercholesterolemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-02-26",
        "link": "https:\/\/www.esperion.com\/investors-media\/press-releases\/?request=aHR0cHM6Ly9lc3Blcmlvbi5nY3Mtd2ViLmNvbS8vbmV3cy1yZWxlYXNlcy9uZXdzLXJlbGVhc2UtZGV0YWlscy9lc3Blcmlvbi1hbm5vdW5jZXMtZmRhLWFwcHJvdmFsLW5leGxpemV0dG0tYmVtcGVkb2ljLWFjaWQtYW5k",
        "note": "FDA Approval announced February 26, 2020.",
        "company_entity_id": 133,
        "company_ticker": "ESPR",
        "company_name": "Esperion Therapeutics Inc.",
        "company_price": "2.0500",
        "company_change": -0.06999999999999995,
        "company_percent_change": -3.3,
        "company_optionable": 1,
        "company_number_of_shares": 185052705,
        "price_change_sparkline": [
            [
                2.14,
                1706677200
            ],
            [
                2.07,
                1706763600
            ],
            [
                2.19,
                1706850000
            ],
            [
                2.38,
                1707109200
            ],
            [
                2.58,
                1707195600
            ],
            [
                2.63,
                1707282000
            ],
            [
                2.58,
                1707368400
            ],
            [
                2.58,
                1707454800
            ],
            [
                2.6,
                1707714000
            ],
            [
                2.54,
                1707800400
            ],
            [
                2.61,
                1707886800
            ],
            [
                2.66,
                1707973200
            ],
            [
                2.69,
                1708059600
            ],
            [
                2.68,
                1708405200
            ],
            [
                2.61,
                1708491600
            ],
            [
                2.63,
                1708578000
            ],
            [
                2.61,
                1708664400
            ],
            [
                2.63,
                1708923600
            ],
            [
                2.9,
                1709010000
            ],
            [
                2.57,
                1709096400
            ],
            [
                2.51,
                1709182800
            ],
            [
                2.55,
                1709269200
            ],
            [
                2.44,
                1709528400
            ],
            [
                2.4,
                1709614800
            ],
            [
                2.46,
                1709701200
            ],
            [
                2.28,
                1709787600
            ],
            [
                2.19,
                1709874000
            ],
            [
                2.12,
                1710129600
            ],
            [
                2.05,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3712,
        "drug_name": "NERLYNX (neratinib) - NALA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Third-line HER2-positive metastatic breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-02-26",
        "link": "https:\/\/investor.pumabiotechnology.com\/news-releases\/news-details\/2020\/Puma-Biotechnology-Receives-US-FDA-Approval-of-Supplemental-New-Drug-Application-for-Neratinib-to-Treat-HER2-Positive-Metastatic-Breast-Cancer\/default.aspx",
        "note": "FDA Approval announced February 26, 2020.",
        "company_entity_id": 238,
        "company_ticker": "PBYI",
        "company_name": "Puma Biotechnology Inc",
        "company_price": "5.3500",
        "company_change": -0.14,
        "company_percent_change": -2.55,
        "company_optionable": 1,
        "company_number_of_shares": 48207162,
        "price_change_sparkline": [
            [
                4.7,
                1706677200
            ],
            [
                4.89,
                1706763600
            ],
            [
                4.72,
                1706850000
            ],
            [
                4.88,
                1707109200
            ],
            [
                5.02,
                1707195600
            ],
            [
                5.04,
                1707282000
            ],
            [
                5.405,
                1707368400
            ],
            [
                5.78,
                1707454800
            ],
            [
                6.36,
                1707714000
            ],
            [
                6.21,
                1707800400
            ],
            [
                7.4,
                1707886800
            ],
            [
                6.99,
                1707973200
            ],
            [
                7.11,
                1708059600
            ],
            [
                6.79,
                1708405200
            ],
            [
                6.51,
                1708491600
            ],
            [
                5.91,
                1708578000
            ],
            [
                6.55,
                1708664400
            ],
            [
                6.48,
                1708923600
            ],
            [
                6.46,
                1709010000
            ],
            [
                6.6,
                1709096400
            ],
            [
                6.22,
                1709182800
            ],
            [
                5.89,
                1709269200
            ],
            [
                5.36,
                1709528400
            ],
            [
                5.18,
                1709614800
            ],
            [
                5.53,
                1709701200
            ],
            [
                5.75,
                1709787600
            ],
            [
                5.35,
                1709874000
            ],
            [
                5.49,
                1710129600
            ],
            [
                5.35,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4551,
        "drug_name": "NURTEC ODT (rimegepant)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Acute treatment of migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-02-27",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/biohavens-nurtec-odt-rimegepant-receives-fda-approval-for-the-acute-treatment-of-migraine-in-adults-301013021.html",
        "note": "FDA Approval announced February 27, 2020.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4551,
        "drug_name": "NURTEC ODT (rimegepant)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Acute treatment of migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-02-27",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/biohavens-nurtec-odt-rimegepant-receives-fda-approval-for-the-acute-treatment-of-migraine-in-adults-301013021.html",
        "note": "FDA Approval announced February 27, 2020.",
        "company_entity_id": 409,
        "company_ticker": "BHVN",
        "company_name": "Biohaven Ltd.",
        "company_price": "58.5800",
        "company_change": 3.2,
        "company_percent_change": 5.78,
        "company_optionable": 1,
        "company_number_of_shares": 81579914,
        "price_change_sparkline": [
            [
                44.48,
                1706677200
            ],
            [
                45,
                1706763600
            ],
            [
                44.79,
                1706850000
            ],
            [
                47.16,
                1707109200
            ],
            [
                47.21,
                1707195600
            ],
            [
                47.26,
                1707282000
            ],
            [
                46.92,
                1707368400
            ],
            [
                48.55,
                1707454800
            ],
            [
                48.71,
                1707714000
            ],
            [
                46.95,
                1707800400
            ],
            [
                47.12,
                1707886800
            ],
            [
                49.11,
                1707973200
            ],
            [
                49.5,
                1708059600
            ],
            [
                47.24,
                1708405200
            ],
            [
                46.57,
                1708491600
            ],
            [
                47.33,
                1708578000
            ],
            [
                47.31,
                1708664400
            ],
            [
                46.18,
                1708923600
            ],
            [
                47.66,
                1709010000
            ],
            [
                47.3,
                1709096400
            ],
            [
                48.14,
                1709182800
            ],
            [
                49.54,
                1709269200
            ],
            [
                56.39,
                1709528400
            ],
            [
                58.65,
                1709614800
            ],
            [
                58.13,
                1709701200
            ],
            [
                58.05,
                1709787600
            ],
            [
                57.97,
                1709874000
            ],
            [
                55.38,
                1710129600
            ],
            [
                58.58,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2784,
        "drug_name": "Isatuximab",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Refractory Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-03-02",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/2cd087df-50cf-4328-a9de-0ecb2c689714",
        "note": "FDA Approval announced March 2, 2020.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2519,
        "drug_name": "OPDIVO (nivolumab) and YERVOY\u00a0(ipilimumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Previously Treated Hepatocellular Carcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-03-11",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200311005141\/en\/",
        "note": "FDA Approval announced March 11, 2020.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6507,
        "drug_name": "EPCLUSA (sofosbuvir \/velpatasvir)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hepatitis C",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-03-19",
        "link": "http:\/\/investors.gilead.com\/news-releases\/news-release-details\/us-food-and-drug-administration-approves-epclusar",
        "note": "sNDA FDA Approval announced March 19, 2020.",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2934,
        "drug_name": "ZEPOSIA (Ozanimod)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsing Multiple Sclerosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-03-25",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200326005222\/en\/",
        "note": "FDA Approval announced March 26, 2020.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5147,
        "drug_name": "IV Triferic",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Anemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-03-27",
        "link": "https:\/\/ir.rockwellmed.com\/news-releases\/news-release-details\/rockwell-medical-inc-receives-fda-approval-trifericr-avnu-ferric",
        "note": "FDA approval announced date March 27, 2020.",
        "company_entity_id": 265,
        "company_ticker": "RMTI",
        "company_name": "Rockwell Medical Inc.",
        "company_price": "1.4400",
        "company_change": -0.09999999999999998,
        "company_percent_change": -6.49,
        "company_optionable": 1,
        "company_number_of_shares": 28489663,
        "price_change_sparkline": [
            [
                1.32,
                1706677200
            ],
            [
                1.3,
                1706763600
            ],
            [
                1.3,
                1706850000
            ],
            [
                1.25,
                1707109200
            ],
            [
                1.26,
                1707195600
            ],
            [
                1.25,
                1707282000
            ],
            [
                1.23,
                1707368400
            ],
            [
                1.3,
                1707454800
            ],
            [
                1.34,
                1707714000
            ],
            [
                1.29,
                1707800400
            ],
            [
                1.29,
                1707886800
            ],
            [
                1.39,
                1707973200
            ],
            [
                1.35,
                1708059600
            ],
            [
                1.34,
                1708405200
            ],
            [
                1.33,
                1708491600
            ],
            [
                1.29,
                1708578000
            ],
            [
                1.26,
                1708664400
            ],
            [
                1.37,
                1708923600
            ],
            [
                1.37,
                1709010000
            ],
            [
                1.36,
                1709096400
            ],
            [
                1.41,
                1709182800
            ],
            [
                1.56,
                1709269200
            ],
            [
                1.47,
                1709528400
            ],
            [
                1.48,
                1709614800
            ],
            [
                1.5,
                1709701200
            ],
            [
                1.53,
                1709787600
            ],
            [
                1.52,
                1709874000
            ],
            [
                1.54,
                1710129600
            ],
            [
                1.44,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6528,
        "drug_name": "TALTZ (ixekizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pediatric Patients with Moderate to Severe Plaque Psoriasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-03-30",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-taltzr-ixekizumab-receives-us-fda-approval-treatment-1",
        "note": "FDA Approval announced March 30, 2020.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2924,
        "drug_name": "REBLOZYL (Luspatercept)",
        "clinical_trial_id": "NCT03682536",
        "has_trial_insight_page": 0,
        "indication": "Myelodysplastic syndromes (MDS) cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-03",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200403005530\/en\/",
        "note": "FDA Approval announced April 3, 2020.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2924,
        "drug_name": "REBLOZYL (Luspatercept)",
        "clinical_trial_id": "NCT03682536",
        "has_trial_insight_page": 0,
        "indication": "Myelodysplastic syndromes (MDS) cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-03",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200403005530\/en\/",
        "note": "FDA Approval announced April 3, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4126,
        "drug_name": "BRAFTOVI (Encorafenib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "BRAF-Mutant Colorectal Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-08",
        "link": "https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2020\/US-FDA-Approves-BRAFTOVI-Encorafenib-in-Combination-with-Cetuximab-for-the-Treatment-of-BRAFV600E-Mutant-Metastatic-Colorectal-Cancer-CRC-After-Prior-Therapy\/default.aspx",
        "note": "FDA Approval announced April 8, 2020.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6567,
        "drug_name": "KOSELUGO (selumetinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Neurofibromatosis type 1 plexiform neurofibromas",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-13",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html",
        "note": "FDA Approval announced April 13, 2020.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6567,
        "drug_name": "KOSELUGO (selumetinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Neurofibromatosis type 1 plexiform neurofibromas",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-13",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html",
        "note": "FDA Approval announced April 13, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2548,
        "drug_name": "Jelmyto (MitoGel)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Urothelial Carcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-15",
        "link": "https:\/\/seekingalpha.com\/pr\/17838341-fda-approves-first-therapy-for-treatment-of-low-grade-upper-tract-urothelial-cancer",
        "note": "FDA Approval announced April 15, 2020.",
        "company_entity_id": 412,
        "company_ticker": "URGN",
        "company_name": "UroGen Pharma Ltd.",
        "company_price": "17.6200",
        "company_change": 0.52,
        "company_percent_change": 3.04,
        "company_optionable": 1,
        "company_number_of_shares": 30866320,
        "price_change_sparkline": [
            [
                15.7,
                1706677200
            ],
            [
                15.9,
                1706763600
            ],
            [
                16.47,
                1706850000
            ],
            [
                15.99,
                1707109200
            ],
            [
                16.01,
                1707195600
            ],
            [
                16.02,
                1707282000
            ],
            [
                18.5,
                1707368400
            ],
            [
                18.98,
                1707454800
            ],
            [
                19.3,
                1707714000
            ],
            [
                18.75,
                1707800400
            ],
            [
                19.22,
                1707886800
            ],
            [
                18.8,
                1707973200
            ],
            [
                19.33,
                1708059600
            ],
            [
                19.24,
                1708405200
            ],
            [
                17.69,
                1708491600
            ],
            [
                17.79,
                1708578000
            ],
            [
                17.09,
                1708664400
            ],
            [
                17.96,
                1708923600
            ],
            [
                18.59,
                1709010000
            ],
            [
                18.17,
                1709096400
            ],
            [
                18.33,
                1709182800
            ],
            [
                17.77,
                1709269200
            ],
            [
                18.42,
                1709528400
            ],
            [
                18.01,
                1709614800
            ],
            [
                18.05,
                1709701200
            ],
            [
                18.03,
                1709787600
            ],
            [
                17.99,
                1709874000
            ],
            [
                17.1,
                1710129600
            ],
            [
                17.62,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3693,
        "drug_name": "TUKYSA (Tucatinib) and HERCEPTIN (Trastuzumab) and XELODA (capecitabine)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "HER2+ Metastatic Breast Cancer (MBC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-17",
        "link": "https:\/\/investor.seattlegenetics.com\/press-releases\/news-details\/2020\/Seattle-Genetics-Announces-US-FDA-Approval-of-TUKYSA-tucatinib-for-People-with-Advanced-Unresectable-or-Metastatic-HER2-Positive-Breast-Cancer\/default.aspx",
        "note": "FDA Approval announced April 17, 2020.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2433,
        "drug_name": "PEMAZYRE (pemigatinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cholangiocarcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-17",
        "link": "https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-treatment-patients-cholangiocarcinoma-cancer-bile-ducts",
        "note": "FDA Approval announced April 17, 2020.",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6204,
        "drug_name": "IMBRUVICA (ibrutinib) and RITUXAN (rituximab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-21",
        "link": "http:\/\/johnsonandjohnson.gcs-web.com\/static-files\/f69ca819-38c5-45b6-be34-ab5969e30765",
        "note": "FDA Approval announced April 21, 2020.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6204,
        "drug_name": "IMBRUVICA (ibrutinib) and RITUXAN (rituximab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-21",
        "link": "http:\/\/johnsonandjohnson.gcs-web.com\/static-files\/f69ca819-38c5-45b6-be34-ab5969e30765",
        "note": "FDA Approval announced April 21, 2020.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3577,
        "drug_name": "TRODELVY (sacituzumab govitecan)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Triple-negative breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-22",
        "link": "http:\/\/www.globenewswire.com\/news-release\/2020\/04\/22\/2020193\/0\/en\/FDA-Grants-Accelerated-Approval-for-Immunomedics-Trodelvy-in-Previously-Treated-Metastatic-Triple-Negative-Breast-Cancer.html",
        "note": "FDA Approval announced April 22, 2020.",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    }
]